Effects of a Growth Mindset of Personality on Emerging Adults' Defender Self-Efficacy, Moral Disengagement, and Perceived Peer Defending.

This study investigated the effects of a brief educational exercise aimed to promote a growth mindset of personality (the belief that personality traits are malleable) on outcomes linked to peer defending. Undergraduates ( = 60) were randomly assigned to complete a learning task designed to foster a growth mindset of personality or to a matching control task. They then read a vignette of a college student victimized by peers and completed paper-and-pencil measures of defender self-efficacy, moral disengagement, and perceived defender behavior, followed by a brief manipulation check.

The effects of protease supplementation on skeletal muscle function and DOMS following downhill running.

Protease supplementation has been shown to attenuate soft tissue injury resulting from intense exercise. The aim of this study was to evaluate the effects of protease supplementation on muscle soreness and contractile performance after downhill running. Ten matched pairs of male participants ran at a -10% grade for 30 min at 80% of their predicted maximal heart rate.

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

The maytansinoid drug DM1 is 100- to 1000-fold more cytotoxic than anticancer drugs that are currently in clinical use. The immunoconjugate C242-DM1 was prepared by conjugating DM1 to the monoclonal antibody C242, which recognizes a mucin-type glycoprotein expressed to various extents by human colorectal cancers. C242-DM1 was found to be highly cytotoxic toward cultured colon cancer cells in an antigen-specific manner and showed remarkable antitumor efficacy in vivo.

Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.

Bis-indolyl-(seco)-1,2,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e compounds are synthetic analogues of CC-1065 that are highly cytotoxic toward a broad spectrum of tumor cell lines. One of these compounds, called DC1, was conjugated to antibodies via novel cleavable disulfide linkers. Conjugates of DC1 with murine mAbs anti-B4 and N901 directed against tumor-associated antigens CD19 and CD56, respectively, proved to be extremely potent and antigen selective in killing target cells in culture.